Idera Pharmaceuticals Historical PE Ratio image   This IDRA PE ratio history page last updated 1/20/2023
Idera Pharmaceuticals Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/14/2022
0.40-1.02-4.08NA
Q2 2022
8/9/2022
0.45-1.70-6.80NA
Q1 2022
5/5/2022
0.43-1.36-5.44NA
Q4 2021
3/31/2022
0.50-1.36-5.44NA
Q3 2021
11/8/2021
0.86-1.87-7.48NA
Q2 2021
8/9/2021
1.07-2.21-8.84NA
Q1 2021
4/29/2021
1.18-4.08-16.32NA
Q4 2020
3/1/2021
4.92-3.74-14.96NA
Q3 2020
10/29/2020
2.93-3.57-14.28NA
Q2 2020
8/4/2020
2.04-4.08-16.32NA
Q1 2020
4/30/2020
1.943.7414.960.1
Q4 2019
3/12/2020
1.06-6.80-27.20NA
Q3 2019
11/6/2019
2.52-6.63-26.52NA
Q2 2019
8/8/2019
2.49-6.63-26.52NA
Q1 2019
5/2/2019
3.06-6.63-26.52NA
Q4 2018
3/6/2019
2.62-7.65-30.60NA
Q3 2018
11/6/2018
7.21-7.31-29.24NA
Q2 2018
8/2/2018
6.20-10.03-40.12NA
Q1 2018
5/9/2018
13.76-13.60-54.40NA
Q4 2017
3/7/2018
16.08-10.88-43.52NA
Q3 2017
11/6/2017
14.48-13.60-54.40NA
Q2 2017
8/7/2017
14.64-19.04-76.16NA
Q1 2017
5/4/2017
16.72-13.60-54.40NA
Q4 2016
3/15/2017
14.641.365.442.7
Q3 2016
10/28/2016
13.20-13.60-54.40NA
Q2 2016
8/2/2016
14.00-14.96-59.84NA
Q1 2016
5/9/2016
11.12-14.96-59.84NA
Q4 2015
3/10/2016
14.24-13.60-54.40NA
Q3 2015
11/6/2015
26.88-13.60-54.40NA
Q2 2015
8/6/2015
24.40-14.96-59.84NA
Q1 2015
5/11/2015
24.40-16.32-65.28NA
Q4 2014
3/12/2015
33.92-19.04-76.16NA
Q3 2014
11/7/2014
19.44-14.96-59.84NA
Q2 2014
8/12/2014
21.92-13.60-54.40NA
Q1 2014
5/13/2014
22.56-16.32-65.28NA
Q4 2013
3/13/2014
44.88-13.60-54.40NA
Q3 2013
11/14/2013
14.32-14.96-59.84NA
Q2 2013
8/15/2013
12.00-20.40-81.60NA
Q1 2013
5/15/2013
6.40-20.40-81.60NA
Q4 2012
3/11/2013
5.36-32.64-130.56NA
Q3 2012
11/12/2012
6.72-23.12-92.48NA
Q2 2012
8/9/2012
8.00-20.40-81.60NA
Idera Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/14/2022
0.40-1.02-4.08NA
Q2 2022
8/9/2022
0.45-1.70-6.29NA
Q1 2022
5/5/2022
0.43-1.36-6.80NA
Q4 2021
3/31/2022
0.50-1.36-9.52NA
Q3 2021
11/8/2021
0.86-1.87-11.90NA
Q2 2021
8/9/2021
1.07-2.21-13.60NA
Q1 2021
4/29/2021
1.18-4.08-15.47NA
Q4 2020
3/1/2021
4.92-3.74-7.65NA
Q3 2020
10/29/2020
2.93-3.57-10.71NA
Q2 2020
8/4/2020
2.04-4.08-13.77NA
Q1 2020
4/30/2020
1.943.74-16.32NA
Q4 2019
3/12/2020
1.06-6.80-26.69NA
Q3 2019
11/6/2019
2.52-6.63-27.54NA
Q2 2019
8/8/2019
2.49-6.63-28.22NA
Q1 2019
5/2/2019
3.06-6.63-31.62NA
Q4 2018
3/6/2019
2.62-7.65-38.59NA
Q3 2018
11/6/2018
7.21-7.31-41.82NA
Q2 2018
8/2/2018
6.20-10.03-48.11NA
Q1 2018
5/9/2018
13.76-13.60-57.12NA
Q4 2017
3/7/2018
16.08-10.88-57.12NA
Q3 2017
11/6/2017
14.48-13.60-44.88NA
Q2 2017
8/7/2017
14.64-19.04-44.88NA
Q1 2017
5/4/2017
16.72-13.60-40.80NA
Q4 2016
3/15/2017
14.641.36-42.16NA
Q3 2016
10/28/2016
13.20-13.60-57.12NA
Q2 2016
8/2/2016
14.00-14.96-57.12NA
Q1 2016
5/9/2016
11.12-14.96-57.12NA
Q4 2015
3/10/2016
14.24-13.60-58.48NA
Q3 2015
11/6/2015
26.88-13.60-63.92NA
Q2 2015
8/6/2015
24.40-14.96-65.28NA
Q1 2015
5/11/2015
24.40-16.32-63.92NA
Q4 2014
3/12/2015
33.92-19.04-63.92NA
Q3 2014
11/7/2014
19.44-14.96-58.48NA
Q2 2014
8/12/2014
21.92-13.60-58.48NA
Q1 2014
5/13/2014
22.56-16.32-65.28NA
Q4 2013
3/13/2014
44.88-13.60-69.36NA
Q3 2013
11/14/2013
14.32-14.96-88.40NA
Q2 2013
8/15/2013
12.00-20.40-96.56NA
Q1 2013
5/15/2013
6.40-20.40-96.56NA
Q4 2012
3/11/2013
5.36-32.64NANA
Q3 2012
11/12/2012
6.72-23.12NANA
Q2 2012
8/9/2012
8.00-20.40NANA
Quotes delayed 20 minutes

Email EnvelopeFree IDRA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Idera Pharmaceuticals (IDRA) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

IDXX PE Ratio History
IDYA PE Ratio History
IGMS PE Ratio History
IIN PE Ratio History
IKNA PE Ratio History
IKT PE Ratio History
ILMN PE Ratio History
IMAC PE Ratio History
IMGN PE Ratio History
IMGO PE Ratio History
How should the IDRA historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Idera Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this IDRA Historical PE Ratio page.

What is the average historical PE for IDRA based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The IDRA historical PE ratio using the annualized quarterly earnings method works out to 1.4.

What is the average historical PE for IDRA based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The IDRA historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Idera Pharmaceuticals Historical PE Ratio information for Idera Pharmaceuticals' stock. The average IDRA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 1.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average IDRA historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this IDRA historical PE result, against the recent PE: when this page was posted on 1/17/2023, the most recent closing price for IDRA had been 0.43, and the most recent quarterly earnings result, annualized, was 14.96. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent IDRA PE on 1/17/2023 based on annualized quarterly EPS was 0.0. Based on IDRA's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the historical average PE across our data set for Idera Pharmaceuticals.

For self directed investors doing their due diligence on IDRA or any other given stock, valuation analysis for IDRA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Idera Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for IDRA. Thanks for visiting, and the next time you need to research IDRA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: TBLT shares outstanding history, Funds Holding MOV, ADAL market cap history.

 

Idera Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.